HomeTag dry eye disease

Stuart Therapeutics, Inc. Announces Successful Phase 2 Clinical Trial Results of its Novel Dry Eye Candidate ST-100

Stuart Therapeutics, Inc. Announces Successful Phase 2 Clinical Trial Results of its Novel Dry Eye Candidate ST-100   – Achieved FDA Pre-Approved Single Primary Endpoint After 28 Days of Administration – Improvement in Total Ocular Discomfort after 14 Days   STUART, Fla., Jan. 3, 2022 /PRNewswire/ — Stuart Therapeutics, Inc. (STUART), a clinical stage, innovative ophthalmic...

Stuart Therapeutics, Inc. Announces Completion of Patient Enrollment in Phase 2 Clinical Trial for Dry Eye Disease

Stuart Therapeutics, Inc. Announces Completion of Patient Enrollment in Phase 2 Clinical Trial for Dry Eye Disease STUART, Fla., Sept. 8, 2021 /PRNewswire/ — Stuart Therapeutics, Inc. (“Stuart“), a clinical stage biopharmaceutical company conducting research and development of unique peptide therapeutics for ophthalmic diseases, today announced that it has completed patient enrollment in its Phase 2...